2-氨基-5-[[[(1S,4S,5R)-4,5-二羟基-1-环戊-2-烯基]氨基]甲基]-1,7-二氢吡咯并[3,2-e]嘧啶-4-酮 | 72496-59-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 中文名称: 2-氨基-5-[[[(1S,4S,5R)-4,5-二羟基-1-环戊-2-烯基]氨基]甲基]-1,7-二氢吡咯并[3,2-e]嘧啶-4-酮
• 英文名称: queuine
• 英文别名: Queuine；2-amino-5-[[[(1S,4S,5R)-4,5-dihydroxycyclopent-2-en-1-yl]amino]methyl]-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one
• CAS: 72496-59-4
• 化学式: C₁₂H₁₅N₅O₃
• 分子量: 277.283
• InChiKey: WYROLENTHWJFLR-ACLDMZEESA-N

物化性质

• 沸点：
  626.3±65.0 °C(Predicted)
• 密度：
  1.87±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO（少许）、甲醇（少许）、水（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  136
• 氢给体数：
  6
• 氢受体数：
  5

ADMET

代谢

奎宁代谢的数据不易获得或访问。

Data regarding the metabolism of queuine is not readily available or accessible.

来源:DrugBank

毒理性

• 毒性总结

奎因是一种天然生物化学物质，可以在人体内自然找到。尽管某些针对小鼠模型的研究表明，该物质缺乏可能导致致命后果，但目前关于奎因的毒性或过量的数据并不容易获得或接触。

Queuine is a natural biochemical that can be found endogenously in the human body. Although certain studies on mouse models have shown that a deficiency in the agent can have fatal consequences, data regarding toxicity or overdosage of queuine is not readily available or accessible.

来源:DrugBank

毒理性

• 蛋白质结合

关于奎尼的蛋白质结合的数据不容易获得或访问。

Data regarding the protein binding of queuine is not readily available or accessible.

来源:DrugBank

吸收、分配和排泄

• 吸收

人类从摄入的食物或肠道菌群中恢复奎因。目前尚未确定从人类微生物群正常更替过程中回收和吸收的奎因比例，但鉴于人类胃肠道中存在的微生物数量，这一比例可能相当显著。此外，考虑到各种嘌呤、嘌呤衍生物和碱类似物在竞争性摄取实验中无法影响奎因的运输，人们认为可能存在一种专用于奎因的转运体。

Humans recover queuine from either ingested food or the gut flora. The proportion of queuine salvaged and absorbed from the normal turnover process of human microbiota has not yet been determined, but it may be significant given the number of microorganisms in the human gastrointestinal tract. Furthermore, it is believed that there may exist a dedicated transporter for queuine, considering various purines, purine-derivatives and base analogs are incapable of affecting queuine transport in competitive uptake experiments.

来源:DrugBank

吸收、分配和排泄

• 消除途径

关于喹喹因消除途径的数据不易获得或无法获取。

Data regarding the route of elimination of queuine is not readily available or accessible.

来源:DrugBank

吸收、分配和排泄

• 分布容积

关于奎宁分布容积的数据不容易获得或访问。

Data regarding the volume of distribution of queuine is not readily available or accessible.

来源:DrugBank

吸收、分配和排泄

• 清除

关于喹因清除的数据不易获得或无法获取。

Data regarding the clearance of queuine is not readily available or accessible.

来源:DrugBank

反应信息

• 作为产物：
  描述：

  7-aminomethyl-7-deazaguanine 生成 2-氨基-5-[[[(1S,4S,5R)-4,5-二羟基-1-环戊-2-烯基]氨基]甲基]-1,7-二氢吡咯并[3,2-e]嘧啶-4-酮
  参考文献：
  名称：

  AKIMOTO, HIROSHI;IMAMIYA, EIKO;HITAKA, TAKENORI;NOMURA, HIROAKI;NISHIMURA+, J. CHEM. SOC. PERKIN TRANS. PT 1,(1988) N 7, C. 1637-1644

  摘要：

  DOI：

文献信息

• [EN] MODIFIED PEPTIDE NUCLEIC ACIDS AND THEIR USE<br/>[FR] ACIDES NUCLÉIQUES PEPTIDIQUES MODIFIÉS ET LEUR UTILISATION
  申请人：UNIV NANYANG TECH

  公开号：WO2016043661A1

  公开（公告）日：2016-03-24

  This invention relates to a peptide nucleic acid comprising the base N4-(2-guanidoethyl)-5-methylcytosine and method for their manufacture. Further, the invention relates to the use of said compounds as medicaments and to methods of targeting the structure of RNAs, particularly in the treatment of viral diseases and cancer.

  这项发明涉及一种包括N4-(2-胍基乙基)-5-甲基胞嘧啶基的肽核酸，以及其制备方法。此外，该发明涉及将所述化合物用作药物以及用于靶向RNA结构的方法，特别是在治疗病毒性疾病和癌症方面。
• [EN] CELLULAR TRANSPORT SYSTEM FOR TRANSFERRING A SULFONIC ACID CONSTRUCT CARRYING A CARGO INTO THE CYTOPLASM OF A CELL<br/>[FR] SYSTÈME DE TRANSPORT CELLULAIRE PERMETTANT DE TRANSFÉRER UNE CONSTRUCTION D'ACIDE SULFONIQUE PORTANT UN CARGO DANS LE CYTOPLASME D'UNE CELLULE
  申请人：SCIENTIST OF FORTUNE SA

  公开号：WO2019068726A1

  公开（公告）日：2019-04-11

  The present invention relates to a cellular transport system for bringing a sulfonic acid construct which carries a cargo into a cell and releasing the cargo in the cell's cytoplasm, the cellular transport system comprising: (i) a sulfonate transporter located in the cytoplasm membrane of the cell wherein said sulfonate transporter is capable of transporting said sulfonic acid construct across the cytoplasm membrane into the cytoplasm; (ii) a γ-glutamyl transferase (GGT; EC 2.3.2.2) which is modified to be located in the cytoplasm of the cell, wherein said γ-glutamyl transferase is capable of hydrolyzing said sulfonic acid construct so as to release the cargo. Moreover, the present invention relates to the use of a cellular transport system for bringing a sulfonic acid construct which contains a cargo into a cell and releasing the cargo in the cell's cytoplasm. Further, the present invention relates to a γ-glutamyl transferase for hydrolyzing a sulfonic acid construct which contains a cargo.

  本发明涉及一种细胞运输系统，用于将携带货物的磺酸构造体带入细胞并在细胞质中释放货物，所述细胞运输系统包括：（i）位于细胞质膜中的磺酸转运蛋白，其中所述磺酸转运蛋白能够将所述磺酸构造体跨越细胞质膜运输至细胞质；（ii）改性为位于细胞质中的γ-谷氨酰转移酶（GGT；EC 2.3.2.2），其中所述γ-谷氨酰转移酶能够水解所述磺酸构造体以释放货物。此外，本发明涉及使用细胞运输系统将携带货物的磺酸构造体带入细胞并在细胞质中释放货物。此外，本发明涉及用于水解携带货物的磺酸构造体的γ-谷氨酰转移酶。
• [EN] MONOCYCLIC, THIENO, PYRIDO, AND PYRROLO PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE OF THE SAME<br/>[FR] COMPOSÉS DE PYRIMIDINES MONOCYCLIQUES, THIÉNOPYRIMIDINES, PYRIDOPYRIMIDINES, ET PYRROLOPYRIMIDINES, LEURS PROCÉDÉS D'UTILISATION ET DE FABRICATION
  申请人：UNIV HOLY GHOST DUQUESNE

  公开号：WO2017031176A1

  公开（公告）日：2017-02-23

  The present invention provides monocyclic, thieno, pyrido and pyrrolo pyrimidine compounds. Pharmaceutical compositions comprising one or more of these compounds and optionally comprising a pharmaceutically acceptable salt or hydrate of one or more of the compounds are provided. Preferably, these pharmaceutical compositions further comprise at least one pharmaceutically acceptable carrier. Methods of treating a patient having cancer are provided wherein a therapeutically effective amount of one or more of these compounds or pharmaceutical compositions are administered to the patient.

  本发明提供了单环、噻吩、吡啶和吡咯基嘧啶化合物。提供了包含这些化合物中的一个或多个的药物组合物，可选地包含一个或多个化合物的药用可接受盐或水合物。优选地，这些药物组合物进一步包含至少一种药用可接受的载体。提供了治疗患有癌症的患者的方法，其中向患者施用了这些化合物或药物组合物中的一个或多个的治疗有效量。
• [EN] TREATMENTS FOR AUTOIMMUNE DISEASE<br/>[FR] TRAITEMENTS POUR MALADIES AUTOIMMUNES
  申请人：PROVOST FELLOWS & SCHOLARS COLLEGE OF THE HOLY UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN

  公开号：WO2016050806A1

  公开（公告）日：2016-04-07

  The invention relates to a novel approach to the treatment of autoimmune diseases, particularly multiple sclerosis.In a further embodiment of the invention there is provided a molecule capable of acting as substrate for the queuine-insertase enzyme complex and where said molecule is not a substrate for Hypoxanthine- guanine phosphoribosyltransferase and said molecule has the effect of lowering interferon gamma, for use in the treatment of auto-immune diseases. Preferably the autoimmune disease is multiple sclerosis.

  该发明涉及一种治疗自身免疫疾病，特别是多发性硬化症的新方法。在该发明的另一实施例中，提供了一种能够作为排队嘌呤插入酶复合物底物的分子，该分子不是次黄嘌呤-鸟嘌呤磷酸核糖转移酶的底物，该分子具有降低干扰素γ的作用，用于治疗自身免疫疾病。最好是多发性硬化症。
• [EN] SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES<br/>[FR] DÉRIVÉS DE PYRIMIDINE SUBSTITUÉS UTILES DANS LE TRAITEMENT DE MALADIES AUTO-IMMUNES
  申请人：PROVOST FELLOWS & SCHOLARS COLLEGE OF THE HOLY UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN

  公开号：WO2016050804A1

  公开（公告）日：2016-04-07

  The present invention describes compounds of formula (I) (I) Wherein: R1 is selected from H and CH3 R2 is selected from H, C4H9 alkyl, C6H13 alkyl and C3H6-phenyl, said phenyl optionally substituted by OH or OCH3, (1R,2S,5S)-5-methylcyclopent-3-ene-1,2-diol X is O or S Y is C, N or S. These compounds have been identified as novel compounds useful in the treatment of multiple sclerosis and other autoimmune diseases.

  本发明描述了化合物的结构为（I）（I）其中：R1可选择H和CH3；R2可选择H、C4H9烷基、C6H13烷基和C3H6-苯基，所述苯基可选择OH或OCH3取代，（1R,2S,5S）-5-甲基环戊-3-烯-1,2-二醇；X可选择O或S；Y可选择C、N或S。这些化合物已被确认为新型化合物，可用于治疗多发性硬化症和其他自身免疫性疾病。